IRIS UniCatt

Lucchini, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.597
EU - Europa 2.277
AS - Asia 2.163
SA - Sud America 473
AF - Africa 91
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.612
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.532
SG - Singapore 1.072
DE - Germania 868
CN - Cina 454
BR - Brasile 394
SE - Svezia 351
IT - Italia 298
VN - Vietnam 181
FR - Francia 175
FI - Finlandia 119
GB - Regno Unito 108
IE - Irlanda 100
ID - Indonesia 78
IN - India 73
JP - Giappone 62
RU - Federazione Russa 51
UA - Ucraina 46
HK - Hong Kong 44
IQ - Iraq 33
CA - Canada 30
PL - Polonia 30
AR - Argentina 29
ZA - Sudafrica 29
BD - Bangladesh 27
CI - Costa d'Avorio 27
KR - Corea 25
TR - Turchia 24
NL - Olanda 23
AT - Austria 20
MX - Messico 17
BE - Belgio 14
EC - Ecuador 13
PK - Pakistan 13
ES - Italia 12
SA - Arabia Saudita 11
CO - Colombia 9
MA - Marocco 9
VE - Venezuela 8
JO - Giordania 7
KE - Kenya 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
IL - Israele 6
TN - Tunisia 6
AU - Australia 5
CH - Svizzera 5
IR - Iran 5
LT - Lituania 5
RS - Serbia 5
UZ - Uzbekistan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
JM - Giamaica 4
KZ - Kazakistan 4
NO - Norvegia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
PT - Portogallo 4
PY - Paraguay 4
SN - Senegal 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
CU - Cuba 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
NI - Nicaragua 3
PE - Perù 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
KH - Cambogia 2
MD - Moldavia 2
MK - Macedonia 2
MT - Malta 2
MY - Malesia 2
OM - Oman 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CY - Cipro 1
EG - Egitto 1
GF - Guiana Francese 1
GR - Grecia 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
Totale 7.605
Salva come PNG Salva come JPEG
Città #
Singapore 622
Chandler 418
Frankfurt am Main 358
San Jose 310
Ashburn 271
Munich 132
Beijing 120
Dublin 100
New York 100
Los Angeles 83
Helsinki 73
Jakarta 67
Lauterbourg 65
Ho Chi Minh City 64
Rome 59
Tokyo 58
Chicago 56
San Mateo 55
Hefei 54
Hanoi 47
Boston 46
São Paulo 41
Hong Kong 38
Princeton 37
Wilmington 37
Nürnberg 30
Milan 29
Moscow 28
Abidjan 27
Dallas 27
The Dalles 26
Ann Arbor 25
Buffalo 23
Redmond 22
Seoul 22
Warsaw 22
Jacksonville 20
Seattle 20
Turku 20
London 19
Salt Lake City 19
Johannesburg 18
Nanjing 18
Cattolica 17
Santa Clara 17
Houston 16
North Bergen 16
Nuremberg 16
Rio de Janeiro 16
Atlanta 15
Fairfield 15
Paris 15
Baghdad 14
Brooklyn 14
Council Bluffs 14
Kent 14
Marseille 14
Pune 14
Bremen 12
Chennai 12
Lappeenranta 11
Orem 11
Düsseldorf 10
Montreal 10
Norwalk 10
Phoenix 10
Amsterdam 9
Brussels 9
Denver 9
Falkenstein 9
Guangzhou 9
Poplar 9
Vienna 9
Ankara 8
Bexley 8
Lawrence 8
Shanghai 8
Woodbridge 8
Amman 7
Belo Horizonte 7
Dearborn 7
Florence 7
Haiphong 7
Hyderabad 7
Portsmouth 7
Redwood City 7
Andover 6
Columbus 6
Elk Grove Village 6
Istanbul 6
Jyväskylä 6
Leawood 6
Mexico City 6
Nairobi 6
Porto Alegre 6
Tampa 6
Tianjin 6
Toronto 6
Bari 5
Boardman 5
Totale 4.280
Salva come PNG Salva come JPEG
Nome #
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 314
Upper body involvement in GNE myopathy assessed by muscle imaging 259
Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations 246
Novel missense variants associated with GNE myopathy 243
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 172
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 163
Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis 162
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience 154
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 146
A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis 146
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 145
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 142
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 142
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis 139
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 135
Novel SEC61G-EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens 133
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 128
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 127
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 127
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 124
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 122
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. 119
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 118
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 117
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 115
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 113
Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments 113
Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features 112
A unique case of multiphasic ADEM or what else? 112
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 112
Ixekizumab exposure associated with myelitis: A case report and a literature review 112
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients 110
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 110
Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis 109
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 107
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 107
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 106
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 105
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 104
Fingolimod vs dimethyl fumarate in multiple sclerosis 102
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 95
COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy 94
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 94
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 93
Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study 91
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 89
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 86
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 86
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study 85
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase 84
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy 84
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 82
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 80
Tumefactive Demyelinating Lesion Around a Developmental Venous Anomaly: A Rare Association 79
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 78
Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review 78
Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis 76
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 76
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 75
Signs and symptoms of COVID-19 in patients with multiple sclerosis 73
Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis 73
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 72
Shift of multiple sclerosis onset towards older age 72
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 69
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 63
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 60
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 33
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 25
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 10
Totale 7.727
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 0 0 0 0 24 40 15
2021/2022476 42 19 8 61 8 15 6 76 32 26 78 105
2022/20231.111 131 139 77 167 69 136 57 104 140 25 46 20
2023/2024636 23 146 26 37 18 110 44 52 10 21 68 81
2024/20251.405 29 37 110 64 64 92 98 68 180 123 335 205
2025/20263.345 464 74 205 375 595 497 553 172 245 165 0 0
Totale 7.727